Accendra Health, Inc.

NYSE:ACH

Medical - Distribution

Healthcare
$0.71 +3.64%

+$0.12 today

Market cap
$54.22M
Beta
1.63
P/E (TTM)
-0.2
EPS (TTM)
-$14.11
52W Low $1.84High $9.55

Volume 1.41M

Average 0.83M

ACH Pre-Tax Margin

Income before tax as a percentage of revenue.

Accendra Health, Inc.NYSE: ACH

Pre-Tax Margin · Q1 FY2026 · quarter ended Mar 2026

Pre-tax margin narrows to -2.6%

Pre-tax margin was -2.6% in Q1 FY2026, down 1.3 pp from a year earlier. On a trailing-twelve-month basis it was -4.2%, up 1.0 pp year over year. Over 3 fiscal years it narrowed by 3.8 pp.

Context

  • Pre-tax margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-2.6%-1.5 pp QoQ
Last fiscal yearDec 2025
-3.7%-0.4 pp YoY
LTMMar 2026
-4.2%+1.0 pp YoY
Pre-Tax Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-1.3 pp——
1 year-0.4 pp——
3 years-3.8 pp——
5 years——
10 years——

Pre-Tax Margin history

Percent of revenue · from the income statement

Latest · FY2025
-3.7%
Year-over-year change
-0.4pp

Pre-Tax Margin vs competitors

How ACH compares with its peers on the latest reported figures

  • ACH's LTM Mar 2026 pre-tax margin of -4.2% is the highest of the 9 companies compared; the peer median is -90.4%.
  • Its year-over-year change of +1.0 pp is the 7th highest of 9, against a peer median of +25.7 pp.
  • Over three fiscal years its change of -3.8 pp compares with a peer median of +73.2 pp.
ACH Competitors Peer median
Pre-Tax Margin for ACH and competitors
Company Period LTM level YoY 3-year change
ACHAccendra Health, Inc.LTM Mar 2026-4.2% +1.0 pp-3.8 pp
HITIHigh Tide Inc.LTM Apr 2026-6.8% -5.2 pp+12.0 pp
SGHTSight Sciences, Inc.LTM Mar 2026-46.9% +16.1 pp+71.2 pp
OMOutset Medical, Inc.LTM Mar 2026-63.0% +35.4 pp+73.2 pp
CVRXCVRx, Inc.LTM Mar 2026-89.2% +8.3 pp+89.8 pp
CGCCanopy Growth CorporationLTM Mar 2026-91.6% +130.4 pp+871.7 pp
EDITEditas Medicine, Inc.LTM Mar 2026-281.6% +419.5 pp+723.2 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-832.6% -100.2 pp-537.5 pp
BIOABioAge Labs, Inc.LTM Mar 2026-871.8% +4024.5 pp—
ALLOAllogene Therapeutics, Inc.FY2025— ——
CABACabaletta Bio, Inc.FY2025— ——
Peer median (excluding ACH) -90.4%+25.7 pp+73.2 pp

Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.79B9.96B10.33B10.7B2.76B
Cost of Revenue8.27B8.13B8.21B8.48B1.56B
Gross Profit1.51B1.83B2.13B2.22B1.2B
Gross Margin15.5%18.3%20.6%20.7%43.5%
Research & Development12.1M0000
Selling, General & Admin1.08B1.55B1.81B1.91B1.05B
Operating Expenses1.14B1.68B2.02B2.43B1.05B
Depreciation & Amortization90.62M228.67M287.38M264.78M214.52M
EBITDA415.47M368.45M390.57M51.22M364.68M
EBITDA Margin4.2%3.7%3.8%0.5%13.2%
Operating Income368.47M142.91M104.51M(207.77M)150.16M
Operating Margin3.8%1.4%1.0%-1.9%5.4%
Interest Income00000
Interest Expense48.09M128.89M157.92M143.8M129.2M
Other Income / Expenses(91.72M)(132.02M)(159.23M)(149.59M)(252.11M)
Income Before Tax276.75M10.89M(54.73M)(357.36M)(101.95M)
Pre-Tax Margin2.8%0.1%-0.5%-3.3%-3.7%
Income Tax Expense55.17M(11.5M)(13.43M)5.33M729K
Net Income221.59M22.39M(41.3M)(362.69M)(1.1B)
Net Margin2.3%0.2%-0.4%-3.4%-39.8%
EPS (Basic)3.050.30(0.54)(4.73)(14.31)
EPS (Diluted)2.940.29(0.54)(4.73)(14.31)
Weighted Avg Shares72.74M74.5M75.79M76.74M76.9M
Weighted Avg Shares (Diluted)75.49M76.22M75.79M76.74M76.9M

Accendra Health, Inc.

NYSE:ACH

Intrinsic Alpha fair value

Locked

Current Price

$0.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.